TY - JOUR AU - Tabernero, J. AU - Yoshino, T. AU - Cohn, A. L. AU - Obermannova, R. AU - Bodoky, G. AU - Garcia-Carbonero, R. PY - 2015 DA - 2015// TI - Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70127-0 DO - 10.1016/S1470-2045(15)70127-0 ID - Tabernero2015 ER - TY - JOUR AU - Ferrara, N. PY - 2004 DA - 2004// TI - Vascular endothelial growth factor as a target for anticancer therapy JO - Oncologist VL - 9 UR - https://doi.org/10.1634/theoncologist.9-suppl_1-2 DO - 10.1634/theoncologist.9-suppl_1-2 ID - Ferrara2004 ER - TY - JOUR AU - Ellis, L. M. AU - Hicklin, D. J. PY - 2008 DA - 2008// TI - VEGF-targeted therapy: mechanisms of anti-tumour activity JO - Nat Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2403 DO - 10.1038/nrc2403 ID - Ellis2008 ER - TY - JOUR AU - Mellor, J. D. AU - Brown, M. P. AU - Irving, H. R. AU - Zalcberg, J. R. AU - Dobrovic, A. PY - 2013 DA - 2013// TI - A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-1 DO - 10.1186/1756-8722-6-1 ID - Mellor2013 ER - TY - JOUR AU - Bennouna, J. AU - Sastre, J. AU - Arnold, D. AU - Osterlund, P. AU - Greil, R. AU - Cutsem, E. PY - 2013 DA - 2013// TI - Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(12)70477-1 DO - 10.1016/S1470-2045(12)70477-1 ID - Bennouna2013 ER - TY - JOUR AU - Cutsem, E. AU - Tabernero, J. AU - Lakomy, R. AU - Prenen, H. AU - Prausova, J. AU - Macarulla, T. PY - 2012 DA - 2012// TI - Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.42.8201 DO - 10.1200/JCO.2012.42.8201 ID - Cutsem2012 ER - TY - JOUR AU - Bates, D. O. AU - Catalano, P. J. AU - Symonds, K. E. AU - Varey, A. H. AU - Ramani, P. AU - O’Dwyer, P. J. PY - 2012 DA - 2012// TI - Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-2223 DO - 10.1158/1078-0432.CCR-12-2223 ID - Bates2012 ER - TY - JOUR AU - Goede, V. AU - Coutelle, O. AU - Neuneier, J. AU - Reinacher-Schick, A. AU - Schnell, R. AU - Koslowsky, T. C. PY - 2010 DA - 2010// TI - Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy JO - Br J Cancer. VL - 103 UR - https://doi.org/10.1038/sj.bjc.6605925 DO - 10.1038/sj.bjc.6605925 ID - Goede2010 ER - TY - JOUR AU - Haas, S. AU - Delmar, P. AU - Bansal, A. T. AU - Moisse, M. AU - Miles, D. W. AU - Leighl, N. PY - 2014 DA - 2014// TI - Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy JO - Angiogenesis. VL - 17 UR - https://doi.org/10.1007/s10456-014-9438-1 DO - 10.1007/s10456-014-9438-1 ID - Haas2014 ER - TY - JOUR AU - Smith, A. D. AU - Roda, D. AU - Yap, T. A. PY - 2014 DA - 2014// TI - Strategies for modern biomarker and drug development in oncology JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0070-8 DO - 10.1186/s13045-014-0070-8 ID - Smith2014 ER -